Zimmer held back by federal probe; Intuitive, NuVasive revenues jump
This article was originally published in Clinica
Executive Summary
Developer of the Coblation soft tissue ablation technology ArthroCare has attributed significant increases in revenue and overall profit for its third-quarter results to the positive performance of its spine business. The Austin, Texas-based firm recorded product sales of $75.5m, aided by a 95% increase in spinal products, compared to the same period the previous year. Its spinal business now accounts for 15% of the company's overall sales and is largely driven by sales in its cavity products and the introduction of its new MD SpineWand soft tissue removal product to the market. ArthroCare claims that the positive performance in Q3 has set the company up to achieve it full year financial goals - it expects total revenue growth for the year to be at least 20%.